India, April 8 -- ProQR Therapeutics N.V. (PRQR), a company developing RNA editing therapies through its Axiomer platform, has unveiled a new AI-driven strategy that includes a partnership with Ginkgo Bioworks and the formation of an AI Advisory Board.
ProQR said it has spent the past 18 months building an AI model designed to significantly speed up and improve the design of editing oligonucleotides used in its RNA editing drug discovery efforts. The company noted that AI is becoming central to scaling its Axiomer platform, which aims to correct scaling its Axiomer platform, which aims to correct disease-causing RNA mutations or modulate protein expression.
As part of the strategy, ProQR has partnered with Ginkgo Bioworks to access Nebula...